CompletedPhase 3

Actinic Keratoses Treatment With Metvix® in Combination With Light

France26 participantsStarted 2015-03-25

Plain-language summary

The main objective of this study is to compare efficacy and safety of Metvix® natural daylight photodynamic therapy with those of Metvix® conventional photodynamic therapy in subjects with mild actinic keratoses (intra-individual comparison)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female above 18 years; * Subject with clinical diagnosis of mild Actinic Keratosis (AK) on the face or the scalp with or without clinical diagnosis of moderate AK on the target areas (TAs); Exclusion Criteria: * Subject with clinical diagnosis of at least one severe AK on TAs * Subject with clinical diagnosis of other skin disease (including non-melanoma skin cancer) on the TAs; * Subject with pigmented AK on the TAs

What they're measuring

Mean Change From Baseline in Total Number of Treated Mild Lesions Per Side at Week 12

Timeframe: Baseline and Week 12

Trial details

NCT IDNCT02373371

SponsorUniversity Hospital, Limoges

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-11-22

Results submitted2019-01-09

View on ClinicalTrials.gov More Actinic Keratoses trials